---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-015503"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2022-06-21T23:59:59+00:00"
generated_at: "2026-06-25T00:12:36.042163+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma appoints Damon DeSantis to Board, replacing Carl DeSantis

## Summary
- Carl DeSantis resigned as Class I Director on June 20, 2022; no disagreement cited.
- Damon DeSantis appointed to fill vacancy, will serve as Class I Director until 2024.
- Damon is son of Carl DeSantis, a principal shareholder, and serves on boards of MacPherson's and Celsius Holdings (CELH).
- Damon received a stock option for 50,000 shares at closing price on June 27, 2022, vesting quarterly through June 2023.

## SEC filing metadata
- accession: 0001437749-22-015503
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2022-06-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 9.01, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774922015503/0001437749-22-015503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774922015503/inbp20220620_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-015503
- JSON: https://secwatch.observer/filing/0001437749-22-015503.json
- Plain text: https://secwatch.observer/filing/0001437749-22-015503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.